Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system
- PMID: 884690
Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system
Abstract
The blood-brain barrier is not as rigid or as formidable as once believed. When experimental tumors of the central nervous system (CNS) and tumors of non-CNS origin are implanted intracerebrally (ic), they will grow and kill the host. It was once thought that only a few select agents, such as the nitrosoureas, were capable of crossing the blood-brain barrier and inhibiting tumor growth. There are now considerable data available which indicate that a variety of agents such as cytosine arabinoside, methotrexate, 6-mercaptopurine, 5-fluorouracil, procarbazine, melphalan, and cyclophosphamide, as well as the nitrosoureas, may significantly influence the growth rate of experimentally implanted ic tumors. A number of physicochemical factors may influence the penetration of the blood-brain barrier. These include pKa values, log-P values, and molecular size. Brain-level measurements indicate that most drugs have some accessibility to the CNS. Maximal effects against sensitive, ic implanted tumors are attained through maximal scheduling. Effective drug combinations should be sought to further enhance antitumor effects in the CNS.
Similar articles
-
Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain.Cancer Res. 1991 Apr 15;51(8):1979-83. Cancer Res. 1991. PMID: 2009516
-
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.Clin Cancer Res. 1998 Jun;4(6):1367-73. Clin Cancer Res. 1998. PMID: 9626452
-
Drug delivery to brain tumours: challenges and progress.Expert Opin Drug Deliv. 2006 Jul;3(4):499-509. doi: 10.1517/17425247.3.4.499. Expert Opin Drug Deliv. 2006. PMID: 16822225 Review.
-
Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier.Cancer Res. 1985 Jun;45(6):2827-33. Cancer Res. 1985. PMID: 2985254
-
The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?Drug Discov Today. 2008 Dec;13(23-24):1099-106. doi: 10.1016/j.drudis.2008.09.005. Epub 2008 Oct 22. Drug Discov Today. 2008. PMID: 18848640 Review.
Cited by
-
Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).J Neurooncol. 1983;1(1):15-9. doi: 10.1007/BF00153636. J Neurooncol. 1983. PMID: 6678302
-
6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.Med Oncol Tumor Pharmacother. 1988;5(3):187-9. doi: 10.1007/BF02986443. Med Oncol Tumor Pharmacother. 1988. PMID: 3166086
-
Dosage and the pharmacokinetics of cytotoxic drugs.Br J Clin Pharmacol. 1979 Sep;8(3):205-7. doi: 10.1111/j.1365-2125.1979.tb01003.x. Br J Clin Pharmacol. 1979. PMID: 497086 Free PMC article. No abstract available.
-
A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.J Neurooncol. 1984;2(1):13-7. doi: 10.1007/BF00165153. J Neurooncol. 1984. PMID: 6088722
-
Time-dependence and selectivity of immunosuppressive agents.Immunology. 1979 Feb;36(2):355-65. Immunology. 1979. PMID: 374250 Free PMC article.